Why the study?
Does enalapril or losartan reduce cardiac mass and arterial pressure in hypertensive rat models?
Does enalapril or losartan reduce cardiac mass and arterial pressure in hypertensive rat models?
Enalapril reduces cardiac mass in high angiotensin II models of hypertension independently of blood pressure reduction, an effect partly mediated by endogenous bradykinin.
Bradykinin partly mediates enalapril's cardiac effects independent of BP in ANGII rats; leaves open translation to human hypertension therapy.
The influence of chronic treatment with enalapril or losartan (10 or 30 mg/kg/24h, respectively) on cardiac mass was evaluated in one-kidney, one clip (1K-1C) hypertensive rats submitted to sodium restriction 3 weeks after clipping and in rats infused for 10 days with angiotensin II (ANGII: 200 ng/kg/min). In 1K-1C hypertension, cardiac mass and arterial pressure were reduced to a similar extent by enalapril and losartan. In ANGII hypertension, enalapril and losartan blunted the increase in cardiac mass whereas losartan but not enalapril prevented the development of hypertension. The cardioprotective effect of enalapril was attenuated by concomitant blockade of bradykinin receptors (Hoe140: 300 micrograms/kg/24h) in both models. The beneficial influence of enalapril on cardiac mass appears to be independent of its effect on blood pressure and ANGII generation and seems partly mediated by endogenous bradykinin in these high ANGII models of hypertension.
No takes yet. Share an insight, caveat, or question.
Hérizi et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: